• search
Antibody Discovery Services Antibody Discovery Services

Antibody Discovery Services

We offer wide range of technology platforms, screening tiers, fit-for-purpose tool and therapeutics for antibody discovery.

A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. The area of antibody discovery has seen tremendous technological advancement, offering pharma companies a wide range of tools to choose from. At Aurigene, we design our antibody discovery programs keeping the therapeutic end point in mind and choose the technology platform accordingly.  

Our team has experience in handling several technology platforms including humanized rodents, B-cell cloning, hybridoma and display libraries. Fit-for-purpose tools and reagent antibodies are generated to meet the program needs.

Speak to our experts

Antigen Generation and Immunization strategies

  • RNA, membrane and whole cell immunization
  • Immunization with conjugate antigens
  • Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
  • Immunization protocols: standard, RImMS and hybrid
  • Neonatal strategy for better epitope specificity and less immunogenic epitope
  • Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays

Hybridoma and B-Cell Cloning

  • Antigen-specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclonal selection
  • Enriched B cell or target-specific B cell fusion methodologies
  • Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridoma

Screening and Evaluation Strategies

  • Multitier high-throughput screening strategies using flow cytometry, ELISA and octet
  • Analytical SE-HPLC, BIAcore, functional assay and mass spectrometry to support analytics
  • Functional assay and fit-for-purpose assay (IHC, Western blotting etc.) for evaluation

Why Aurigene Pharmaceutical Services?

Single B-cell cloning

Humanized rodent platform

Display platforms (Phage/ Yeast)

Hybridoma

Virtual Tour

 
The importance of business continuity planning in CRDMO industry

NOVEMBER 16, 2023

The importance of business continuity planning in CRDMO industry

Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...

Read More

cGMP Development and Manufacturing Services

Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...

Read More

Systematic formulation design - shorten development cost & time

Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...

Read More

Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions

2016

Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack